EP Patent

EP0255002A1 — New pharmaceutical formulations with programmed release containing antiphlogistics

Assigned to Alfa Wasserman SpA · Expires 1988-02-03 · 38y expired

What this patent protects

New galenic formulations with programmed release, to be administered by oral route, containing as the active ingredient a compound endowed with antiphlogistic, analgesic and antipyretic activity like, for instance, an arylacetic or an arylpropionic acid and the pharmaceutical­ly …

USPTO Abstract

New galenic formulations with programmed release, to be administered by oral route, containing as the active ingredient a compound endowed with antiphlogistic, analgesic and antipyretic activity like, for instance, an arylacetic or an arylpropionic acid and the pharmaceutical­ly acceptable salts thereof. In these new formulations, a portion of the active ingredient is released in a short time, so that the drug can quickly develop its therapeutic action reaching the necessary hematic levels, while the remaining portion of the active constituent is released in a longer interval of time so as to allow the therapeutic coverage till the subsequent administration. Said therapeutic coverage can even last 24 hours; thus the new galenic formulations object of the present invention are suitable for a once a day administration.

Drugs covered by this patent

Patent Metadata

Patent number
EP0255002A1
Jurisdiction
EP
Classification
—
Expires
1988-02-03
Drug substance claim
No
Drug product claim
No
Assignee
Alfa Wasserman SpA
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.